PubRank

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Clinical Trial ID NCT00680901

PubWeight™ 31.69‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00680901

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009 6.28
2 Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial. J Clin Oncol 2015 2.30
3 Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol 2013 1.72
4 Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011 1.43
5 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012 1.33
6 Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist 2012 1.10
7 Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol 2011 1.08
8 Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist 2013 1.06
9 Targeting receptor tyrosine kinases in gastric cancer. World J Gastroenterol 2014 0.98
10 Metastatic gastric cancer - focus on targeted therapies. Biologics 2012 0.96
11 Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol 2014 0.92
12 The progress of targeted therapy in advanced gastric cancer. Biomark Res 2013 0.89
13 Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel) 2013 0.87
14 Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol 2013 0.87
15 New developments in the treatment of metastatic gastric cancer: focus on trastuzumab. Onco Targets Ther 2011 0.84
16 Molecular targeting to treat gastric cancer. World J Gastroenterol 2014 0.84
17 Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J Gastroenterol 2014 0.83
18 Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. Therap Adv Gastroenterol 2012 0.83
19 Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. Exp Mol Med 2013 0.82
20 Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. World J Gastroenterol 2013 0.82
21 Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome. World J Gastroenterol 2014 0.79
22 Personalized medicine in gastric cancer: Where are we and where are we going? World J Gastroenterol 2016 0.79
23 Gastric Cancer: New Drugs - New Strategies. Gastrointest Tumors 2015 0.78
24 New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013 0.77
25 Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol 2016 0.75
26 Novel therapy for advanced gastric cancer. World J Gastrointest Oncol 2015 0.75
27 Accomplishments in 2008 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res 2009 0.75
28 Targeting metastatic upper gastrointestinal adenocarcinomas. World J Clin Oncol 2011 0.75
Next 100